Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
The most frequent type of lymphoblastic lymphoma. It comprises approximately 85-90% of cases. It is more frequently seen in adolescent males. It frequently presents with a mass lesion in the mediastinum. Pleural effusions are common. (WHO, 2001)
Biomarker and diagnostic research for T-lymphoblastic lymphoma has been reported in the published literature.
16 clinical trials registered, 3 recruiting. Interventions under study include drug therapy, procedural interventions, biologic therapy, and other interventions. Pipeline includes 2 PHASE3, 2 PHASE2, 9 PHASE1. Research is sponsored by a mix of industry and academic institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT06136364](https://clinicaltrials.gov/study/NCT06136364) |
Data assembled from 3 of 12 sources · Last updated Sep 19, 2026, 3:31 AM UTC
Common questions about T-lymphoblastic lymphoma
CD7 CAR-T in Adults With Relapsed or Refractory T-LBL/ALL Clinical Study |
PHASE1 |
Hebei Senlang Biotechnology Inc., Ltd. |
RECRUITING |
[NCT07523555](https://clinicaltrials.gov/study/NCT07523555) | Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies | PHASE1 | Beijing Biotech | RECRUITING |
[NCT06376721](https://clinicaltrials.gov/study/NCT06376721) | Linperlisib Combined With Camrelizumab and Pegaspargase in Advanced or Relapsed/Refractory NK/T-cell Lymphoma | PHASE1 | Beijing Tongren Hospital | RECRUITING |
80 publications have been identified in PubMed for T-lymphoblastic lymphoma. Research spans Case Report / Case Series (39%), Review / Meta-Analysis (16%), and Other (14%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 31 | 39% |
Research summaries | 13 | 16% |
Other research | 11 | 14% |
Disease patterns and progression | 10 | 13% |
Testing and diagnosis research | 6 | 8% |
Clinical study results | 5 | 6% |
Laboratory research | 4 | 5% |
Yang Q (2026). [PMID: 41766881](https://pubmed.ncbi.nlm.nih.gov/41766881/). *Front Immunol*. [Case Report / Case Series]
Son BA (2026). [PMID: 42068660](https://pubmed.ncbi.nlm.nih.gov/42068660/). *Curr Res Transl Med*. [Case Report / Case Series]
Ströbel P (2026). [PMID: 41537898](https://pubmed.ncbi.nlm.nih.gov/41537898/). *Pathologie (Heidelb)*. [Review / Meta-Analysis]
Antiri EK (2026). [PMID: 41810412](https://pubmed.ncbi.nlm.nih.gov/41810412/). *Case Rep Pathol*. [Case Report / Case Series]
Cozzolino I (2026). [PMID: 41628100](https://pubmed.ncbi.nlm.nih.gov/41628100/). *Acta Cytol*. [Review / Meta-Analysis]
Kamitori T (2026). [PMID: 42237638](https://pubmed.ncbi.nlm.nih.gov/42237638/). *Pediatr Blood Cancer*. [Other]
Guo W (2026). [PMID: 41299066](https://pubmed.ncbi.nlm.nih.gov/41299066/). *Oncogene*. [Basic Science / Preclinical]
Khatib L (2026). [PMID: 41467249](https://pubmed.ncbi.nlm.nih.gov/41467249/). *Pediatr Blood Cancer*. [Other]
Shen X (2026). [PMID: 42141436](https://pubmed.ncbi.nlm.nih.gov/42141436/). *J Cardiothorac Surg*. [Other]
Cheng Q (2026). [PMID: 42178614](https://pubmed.ncbi.nlm.nih.gov/42178614/). *Br J Haematol*. [Epidemiology / Natural History]
AI-curated news mentioning T-lymphoblastic lymphoma
Updated Mar 8, 2026
A case study highlights advanced lymphoblastic lymphoma in the leukaemic phase, which resulted in sudden and fatal CNS hemorrhage. This underscores the critical need for awareness and research into the aggressive nature of this lymphoma variant.